

ForPatients

by Roche

Prostate Cancer Metastatic Prostate Cancer

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Trial Status
Completed

Trial Runs In
26 Countries

Trial Identifier
NCT03072238 CO39303

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03072238 CO39303
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥ 18 Years

Healthy Volunteers
No
